Bellicum Pharmaceuticals (BLCM) : 3-month performance

• The University of Texas MD Anderson Cancer Center acquired Bellicum Pharmaceuticals in February 2024. The acquisition included Bellicum's cell therapy technologies, intellectual property, and clinical-grade stocks. MD Anderson also acquired Bellicum's Houston facility in 2020.